CytomX Therapeutics Inc Cash Flow Quality Index

Latest as of March 2025: -0.89x

CytomX Therapeutics Inc cash flow quality index. CytomX Therapeutics Inc (CTMX) has a Cash Flow Quality Index of -0.89x as of March 2025. Operating cash flow of $-21.04 Million is below net income of $23.52 Million, suggesting accrual-heavy earnings not yet converted to cash. See CytomX Therapeutics Inc (CTMX) flexibility index to measure the company's free cash flow as a share of total liabilities.

Cash Flow Quality Index

-0.89x

Operating CF / Net Income

Operating Cash Flow

$-21.04 Million

USD

Net Income

$23.52 Million

USD

Data as of

Mar 2025

Most recent filing

Cash Flow Quality Index of CytomX Therapeutics Inc (2024–2024)

Cash flow quality index of CytomX Therapeutics Inc from 2024 to 2024. Historical Cash Flow Quality Index for CytomX Therapeutics Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore CTMX operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.

CytomX Therapeutics Inc Cash Flow Quality Index by Year (2024–2024)

CytomX Therapeutics Inc cash flow quality index by year from 2024 to 2024. Year-by-year earnings quality comparison for CytomX Therapeutics Inc. For the full cash flow conversion analysis, see CTMX cash generation efficiency.

Year	Quality Index	Operating CF (USD)	Net Income	YoY Change
2024	-2.71x	$-86.23 Million	$31.87 Million	—

Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.